Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BMEA
Strong SellHot AirBiomea Fusion, Inc. · Healthcare · United States · $125M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing novel covalent small molecule drugs to treat cancer and other serious diseases. The company's lead product candidates are designed to specifically target and permanently bind to disease-driving proteins, offering potentially more durable and efficacious therapeutic options. Its proprietary FUSION System platform underpins its competitive strategy, aiming to create best-in-class covalent medicines.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.14 | -1.71 | -3.83 | -1.18 | — | -0.18 | -0.84 | -0.94 | — |
| Shares | 72.3M | 72.3M | 36.3M | 72.3M | 0.0% | 72.3M | — | — | — |
| Debt | 2.3M | 10.3M | 8.8M | 1.6M | -11.4% | 0.9M | — | — | — |
| Equity | 108.5M | 169.2M | 51.6M | 29.6M | -35.2% | — | — | — | — |
| Op CF | -62.4M | -96.6M | -119.9M | -70.4M | — | -47.2M | — | — | — |
| Inv CF | 27.3M | -2.2M | -0.4M | 0 | — | — | — | — | — |
| Fin CF | 1.2M | 163.8M | 1.7M | 67.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BMEA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BMEA | Biomea Fusion, Inc.(you) | $125M | 16 | Strong Sell |
| VTVT | vTv Therapeutics Inc. | $128M | 18 | Strong Sell |
| AARD | Aardvark Therapeutics, Inc. | $127M | 18 | Strong Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
| GUTS | Fractyl Health, Inc. | $105M | 14 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 11 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| BDTX | Black Diamond Therapeutics, Inc. | $128M | 22 | Sell |
| UNCY | Unicycive Therapeutics, Inc. | $144M | 12 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%